Anti-APP(solanezumab biosimilar) mAb Cat. No. BME100671



PRODUCT INFORMATION

Common Name	LY-2062430;LY 2062430;LY206430
Synonyms	AAA;AD1;PN2;ABPP;APPI;CVAP;ABETA;PN-II;preA4;CTFgamma;alpha-sAPP
Applications	N/A
Recommended Dilutions	N/A
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	N/A
lgG type	lgG1
Reactivity	Human
Target	APP
Uniprot ID	P05067
Description	Anti-APP(solanezumab biosimilar[]lgG1) mAb
Delivery	3-4 weeks
Storage & Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only
Conjugate	Unconjugated
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

Email: info@dimabio.com Website: www.dimabio.com

